nab-paclitaxel + bevacizumab + lobaplatin

This is a combination therapy consisting of three components: - **Nab-paclitaxel**: A 130-nm albumin-bound formulation of paclitaxel that can enhance drug delivery to tumors and increase intra-tumor drug concentration compared to solvent-based paclitaxel. It also minimizes hypersensitivity reactions due to the absence of solvents. - **Bevacizumab**: An anti-VEGF monoclonal antibody that targets angiogenesis. - **Lobaplatin**: A platinum-based chemotherapeutic agent. While combinations of nab-paclitaxel and bevacizumab (sometimes with carboplatin) have been studied in various cancers including non-small cell lung cancer (NSCLC) and triple-negative metastatic breast cancer, the specific combination with lobaplatin is not well documented in the provided information.